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Instituto Carlos III, Madrid, SpainSummary patients with advanced HCC [2], mainly by delaying tumor progres-The high failure rate of phase 3 trials in oncology is forcing the
scientiﬁc community to rethink drug development strategies
and optimize trial design. The current paradigm of systemic ther-
apies is progressively favoring molecular-based patient selection.
In hepatocellular carcinoma, four out of the ﬁve phase 3 trials
that tested molecular therapies in the last 5 years have been neg-
ative. None of them included enriched populations using pre-
dicted biomarkers of response. Hence, there is an increasing
need to provide new targets and reﬁne selection criteria in HCC
clinical trials using molecular readouts of tumor biology.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Lessons from negative trials in hepatocellular carcinoma
Disease burden due to hepatocellular carcinoma (HCC) continues to
grow. Mortality related to this cancer has increased by more than
50% in the last 20 years, worldwide [1]. In fact, among the leading
cancer causes of disability-adjusted life years (i.e., sum of years lost
due to prematuremortality andyears livedwithdisability), liver can-
cer shows one of the highest increases [1]. Despite these dismal data,
there have been major achievements in the clinical management of
HCC. For example, the application of curative therapies such as surgi-
cal resection or transplantation provides good survival rates, beyond
65% at 5 years. Unfortunately, most patients are diagnosed at inter-
mediate or advanced stages were curative options are not recom-
mended [2]. This emphasizes the need to direct resources to
improve HCC early detection by fully deploying surveillance pro-
grams in patients at high risk [2]. When available, effective HCC che-
moprevention in cirrhotic patientswill also have apositive impact on
liver cancer worldwide. A recent phase 3 randomized controlled trial
(RCT) demonstrated that a molecular targeted agent, sorafenib, was
able to signiﬁcantly improve survival from 7.9 to 10.7 months inJournal of Hepatology 20
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Open access under CC BY-NC-sion [3]. These positive results obtained with a so-called molecular
therapy prompted the proliferation of clinical trials testing different
targeted therapies in HCC, both in ﬁrst and second line [4]. However,
initial results of these follow-up trials have been discouraging and
suggest that HCC treatment is far more complex that initially antici-
pated. These recent failures also highlight the need for novel targets
and new strategies for drug evaluation in the molecular therapy
era.
By the end of 2012, four drugs (i.e., sunitinib, erlotinib, linifa-
nib, and brivanib) have been unable to improve or parallel sorafe-
nib’s results in large phase 3 randomized controlled trials (RCT),
despite some of themwere reported to have some efﬁcacy signals
in phase 2. Some of these drugs share molecular targets with
sorafenib like VEGFR or PDGFR, while others add additional
blockade activity against CKIT, EGFR, and FGFR (Table 1). Results
of these trials follow the overall low success rate of phase 3 RCT
in other malignancies, usually with a positive rate of less than
30%, and an estimated cost of $2.5 billion lost per year [5]. Differ-
ent strategies have been suggested to revert this negative trend,
including (a) improvements in trial design (e.g., encouraging
interim analyses, adaptive trial design, etc.), (b) a thorough re-
evaluation of the criteria utilized to identify efﬁcacy signals in
phase 2 trials, (c) identiﬁcation of new molecular targets, and
(d) improvements in patient selection. For the case of HCC, we
will brieﬂy discuss the latter two.
A number of phase 3 RCT are currently evaluating molecular
therapies in advanced HCC, most of them in second line (Table 1).
They are testing drugs with blockade activity against mTOR
(everolimus), VEGFR (ramucirumab, regorafenib), TIE2 (regorafe-
nib), MET (tivantinib), and PDGFR (regorafenib). Only one of them
includes patients based on tumor activation of its predicted tar-
get (i.e., MET receptor and tivantinib), which indicates that there
is still a long way to go for personalized medicine in trial design
for HCC. Nevertheless, positive results of trial enrichment based
on oncogene addiction loops in other malignancies are starting
to dissipate the reasonable concerns about this new approach.High-throughput era: Novel targets
The last decade has witnessed a revolution in how scientists
study cancer genomes. The emergence and rapid development
of sequencing technologies have dramatically impacted13 vol. 59 j 392–395
ND license.
Table 1. Phase 3 clinical trials testing molecular targeted therapies in advanced HCC.
Drug Main targets Indication Biomarker-trial enrichment Status
Sorafenib BRAF, VEGFR, PDGFR First line None Approved
Sunitinib VEGFR, KIT, PDGFR First line None Negative
Brivanib FGFR, VEGFR First and second line None Negative
Linifanib VEGFR, PDGFR First line None Negative
Erlotinib EGFR First line None Negative
Regorafenib VEGFR, TIE2, PDGFR Second line None Ongoing
Everolimus MTOR Second line None Ongoing
Ramucirumab VEGFR Second line None Ongoing
Tivantinib MET Second line High MET (immunohistochemistry) Ongoing
JOURNAL OF HEPATOLOGYbiomedical research, particularly in the ﬁeld of target discovery
in oncology [6]. Nowadays, it is possible to obtain the complete
nucleotide sequence of a given tumor, which enables the identi-
ﬁcation of new mutations, copy number changes, and fusion
events. The addition of data from epigenetic alterations provides
new opportunities to dissect the molecular determinants of
tumor development and progression. This vast amount of raw
data makes functional data integration a major challenge, and
sets a new ground for the deployment of personalized medicine
approaches in cancer care.
These new techniques have been applied to study HCC. Dif-
ferent studies corroborate that mutations in TP53 and CTNNB1
are the most prevalent in HCC, being in fact mutually exclusive
[7]. They also underscore the role of chromatin remodeling
aberrations in a subgroup of HCC, mostly through mutations
in ARID1A and ARID2 [8]. Additional genes with frequent muta-
tions in HCC include NFE2L2 and the MLL family of histone
methyltransferases. Genomic sequencing also conﬁrmed HBV
integrations at cancer-related genes such as TERT, MLL4, and
CCNE1. Exome sequencing also enabled the identiﬁcation of
tumor suppressor properties for IRF2, whose inactivation led
to impaired TP53 function [7]. A major bottleneck of these stud-
ies relates to a limited power for functional validation. Unfortu-
nately, the large number of low frequency mutations
determines that only a handful of these candidates will be fur-
ther tested in animal models, despite recent improvements in
strategies for cancer modeling in vivo [9]. Considering that some
of these low prevalence mutations may harbor oncogene addic-
tion loops (discussed below), it is obvious that more extensive
validation approaches will be required in the future. Besides
mutations, deep sequencing will potential unleash chromosomal
rearrangements and fusion proteins. Although fusion events
have been mostly described in hematological malignancies,
some reports found them in solid tumors, and they may poten-
tially behave like oncogenic addiction loops [10].
Besides sequencing data, numerous studies implicate epige-
netic aberrations in HCC development and progression. The epi-
genome refers to those chemical changes unrelated to DNA
nucleotide sequence but with an impact on cellular phenotype
through modulation of gene expression. The epigenetic machin-
ery involves DNA methylation, histone modiﬁcations, and nucle-
osome positioning [11]. Potential DNA methylation sites are
mostly cytosines when followed by a guanine (i.e., CpG dinucle-
otides). CpG sites tend to cluster, forming CpG islands, and locate
in gene promoters where they control transcription initiation.Journal of Hepatology 201Human cancers are characterized by a global DNA hypomethyla-
tion, which correlates with increased genomic instability. Also,
malignant tumors have selective hypermethylation of CpG
islands in promoter regions of tumor suppressor genes. Besides
DNA methylation, histone modiﬁcations can also regulate gene
expression. Numerous reagents able to modify DNA methylation
and histone conformation have been tested in human cancer, and
four of them have received FDA approval, for myelodysplastic
syndromes and cutaneous T-cell lymphoma. In HCC, preclinical
evidence suggests antitumor activity for a histone deacetylase
inhibitor (panobinostat [12]), but clinical studies are still in early
developmental phases. Novel treatment modalities currently
under early clinical phases include the oncolytic and immuno-
therapeutic vaccine virus (JX-594). An uncontrolled small phase
2 trial has recently shown 15% objective responses and median
survival of 9 months (14.1 in patients receiving higher doses of
JX-594 [13]) in patients with advanced HCC. Despite being early
phase and taking results with caution, the study opens new ther-
apeutic paths for immunotherapy and viral mediated drug deliv-
ery in HCC. Other emerging sources of HCC therapeutics involve
underexplored pathways in HCC, such as autophagy, the role of
lymphotoxins, gut microbiota, etc. [14].Molecular-based patient selection
In 2008, a panel of experts reported a set of recommendations for
HCC trial design using evidence-based principles. They covered
different aspects of HCC clinical research such as end points,
assessment of response, stratiﬁcation strategies and unmet
research needs [15]. Regarding patient selection, recommenda-
tions emphasized the need for a homogenization of inclusion cri-
teria based on BCLC stage and liver function. Enrichment
strategies using molecular biomarkers were barely mentioned,
despite the fact that they forecast a future role of molecular-
based tumor classiﬁcation in trial design.
The search for molecular predictors of response is becoming a
standard practice in clinical oncology research. This model of
patient selection relies on the concept of oncogenic addiction,
which basically requires a priori knowledge of the speciﬁc molec-
ular alterations responsible for tumor progression on an individ-
ual basis [16]. There are different successful examples of this
approach, but it is remarkable the recent introduction of crizoti-
nib in ALK+ lung cancer. Brieﬂy, between 2007 and 2009 a series
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Fig. 1. Molecular-based trial design in hepatocellular carcinoma (HCC): current guidelines for trial design in HCC recommend unifying clinical criteria for patient
inclusion based on stage (BCLC algorithm) and liver function (Child-Pugh score). Recent negative results of phase 3 trials with molecular therapies suggest that an
additional level of uniformity based on molecular parameters could eventually increase the odds of positive trial results using this type of compounds. Patient
randomization within enriched populations, based on oncogene addiction loops or signaling pathway deregulation, has shown its efﬁcacy in other solid tumors.
Clinical Application of Basic Scienceevent involving the ALK gene in a minority of lung cancers
(<5%) [17,18]. This rearrangement shows pro-oncogenic proper-
ties in experimental models of the disease [19]. Subsequent
non-randomized phase 2 trials enriched in ALK+ patients trea-
ted with crizotinib, an ALK inhibitor, showed striking results in
terms of response [10], and granted accelerated FDA approval
of the drug. Furthermore, a recent landmark phase 3 RCT
enrolling 347 patients with ALK+ lung cancer, randomized to
receive either crizotinib or standard chemotherapy, demon-
strated how crizotinib signiﬁcantly increased progression-free
survival from 3 to 7.7 months, with a hazard of 0.49 [20]. This
trial further conﬁrms the validity of a molecular-based
patient selection approach to maximize therapeutic response.
A similar approach should be adopted for HCC drug develop-
ment (Fig. 1).
Unlike other solid tumors (e.g., lung, melanoma, colon,
breast, and gastric), there is no clinical validation of any onco-
genic addiction loop in HCC. It is also disappointing that none
of the aforementioned, negative trials testing molecular thera-
pies in HCC included patient enrichment based on biomarkers
of signaling pathway deregulation (Table 1). For example,
despite the fact that around 10% of HCC patients have ampliﬁca-
tions affecting the FGF19 locus [21] – a known activator of FGF
signaling – none of the trials testing the FGFR inhibitor brivanib
used this or other biomarkers of FGF cascade activation as an
inclusion criterion. In other words, an eventual positive effect
of brivanib in patients with activation of FGF signaling could
be diluted, since trials probably enrolled patients with and
without FGF activation, being the former probably less in num-
ber. Nevertheless, there are preliminary data that challenge this
classic paradigm of trial design in HCC. A recent randomized
phase 2 trial testing an MET inhibitor (i.e., tivantinib) in patients394 Journal of Hepatology 201with advanced HCC in second line, showed positive results in
patients with tumoral overexpression of MET [22]. A phase 3
RCT will elucidate whether tivantinib is clinically useful in
HCC with MET overexpression. Besides reﬁning selection criteria
based on molecular parameters, some recent trials also highlight
the need to reconsider current surrogate end points of survival.
For example, in the second-line phase-3 trial, brivanib signiﬁ-
cantly delayed time-to-progression (TTP) without having a par-
allel impact on overall survival.
Intratumor heterogeneity has emerged as a potential draw-
back for personalized medicine approaches in cancer [23]. Deep
sequencing studies indicates that molecular biomarkers
obtained from tumor single-biopsy specimens may underesti-
mate mutation burden, at least in renal cancer [24]. Despite that
histologic heterogeneity is a known feature in HCC, there are no
solid data at the molecular level. The cause for this heterogene-
ity probably relates to evolutionary changes in cancers framed
within the clonal evolution hypothesis. It may also justify the
lack of efﬁcacy of some targeted therapies and explain a mech-
anism of acquired resistance in tumors. Since a scenario where
patients with advanced HCC undergo multiple biopsies to assess
their mutation spectrum is fairly unrealistic, new tools need to
be developed to infer molecular heterogeneity non-invasively.
One of the most appealing relies on molecular information
obtained from circulating tumor cells (CTC), whose presence
correlates with tumor dissemination and patient prognosis
[25]. Another alternative exploits the varying imaging behavior
of HCC depending on the different tumor expression proﬁles
[26]. It seems equally impractical to treat all of the driver muta-
tions present in a given tumor, particularly considering drug
toxicity in cirrhosis. Eventually, target prioritization strategies
will also be needed.3 vol. 59 j 392–395
JOURNAL OF HEPATOLOGYKey Points
• Molecular targeted therapies improve survival in
hepatocellular carcinoma (HCC). Sorafenib is the
standard-of-care for patients at advanced stages
• Cumulative failures in phase 3 trials with molecular
agents underscore the need for new targets and better
patient selection strategies in HCC drug development
• Emerging data on deep sequencing and epigenetics
are providing new grounds for target discovery in
HCC, including emerging pathways such as chromatin
remodeling
• Current approaches in trial design tend to match drugs
with the best candidates based on molecular data.
Successes achieved in other tumors (e.g., crizotinib in
ALK+ lung cancer) lend credit to this approach
In summary and taking some perspective, the ﬁrst ﬁve years
since the introduction of molecular therapies, sorafenib, in HCC
have been both exciting and challenging. The initial optimism
is being substituted by the certainty that HCC therapy will be
increasingly complex and that drug toxicity will be a major bot-
tleneck for combination therapies. To improve sorafenib results,
novel treatments should go beyond the ‘classical’ oncogenic tar-
gets. The role of less conventional therapies such as immunother-
apy is yet to be established. Furthermore, design of prospective
clinical trials will need to focus on best responders using
biomarkers.Conﬂict of interest
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